Analyst RatingAnalyst reiterates a Buy rating with a new $20 PT.
Clinical Trial ResultsEfficacy continues to be compelling, with CR rates ranging from 73-89% across the 180mg Q8W OLE and 240mg/360mg single dose cohorts.
LeadershipDr. Daniel Adelman, an experienced clinical development executive, will assume the role of acting CMO, bringing expertise in immunology and asthmatic conditions.